Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease

NCT03330470 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-05-28

No results posted yet for this study

Summary

The purpose of this study is to investigate the beneficial effects of regular exercise and the impact of food supplement carnosine on cognitive, motoric and metabolic functions as well as on specific biologically active substances in volunteers with subjective (SCI) or mild (MCI) cognitive impairment, as well as in patients in early stages of Parkinson's disease. The investigators assume the immediate intervention-associated health benefit for volunteers.

Conditions

Interventions

BEHAVIORAL

exercise

participants will be subjected to 4 months supervised exercise intervention

DIETARY_SUPPLEMENT

carnosine supplementation

participants will be instructed to take carnosine 2 times daily

BEHAVIORAL

stretching

participants will be subjected to 4 months supervised stretching program

DIETARY_SUPPLEMENT

supplementation with placebo

participants will be instructed to take placebo 2 times daily

Sponsors & Collaborators

  • Comenius University

    collaborator OTHER
  • University Hospital Bratislava

    collaborator OTHER
  • National Cheng Kung University

    collaborator OTHER
  • Slovak Academy of Sciences

    lead OTHER_GOV

Principal Investigators

  • Peter Turčáni, Prof., MD, PhD · University Hospital Bratislava, Comenius University, Bratislava,

  • Peter Valkovič, Prof., MD, PhD · University Hospital Bratislava, Comenius University, Bratislava,

  • Barbara Ukropcová, Assoc. Prof., MD, PhD · Biomedical Research Center, Slovak Academy of Sciences,

  • Jozef Ukropec, DrSc, PhD · Biomedical Research Center, Slovak Academy of Sciences,

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2023-06-30
Completion
2023-09-30

Countries

  • Slovakia
  • Taiwan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03330470 on ClinicalTrials.gov